Matt Abernethy, Chief Financial Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX), a company currently valued at $11.4 billion with strong financial health according to InvestingPro analysis, ...

Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences ...

Julie Cooke, Chief Human Resources Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently sold company shares valued at $181,129. The transactions, executed on February 13, 2025, involved the ...

We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Deutsche Bank initiated coverage of Neurocrine (NBIX) with a Hold rating and $138 price target Maximize Your Portfolio with Data Driven ...

Guggenheim lowered the firm’s price target on Neurocrine (NBIX) to $163 from $165 and keeps a Buy rating on the shares after the company ...

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Monday. A ...

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective reduced by Guggenheim from $165.00 to $163.00 in a report published on Monday,Benzinga reports. They currently have a buy ...

Of the trio, the most drastic cutter was UBS's Ashwani Verma, who reduced his level on Neurocrine to $154 per share from his preceding $176. According to reports, Verma cited uninspiring guidance ...